Items where Author is "Hebeisen, Paul"

2021

Borsari, Chiara and Keles, Erhan and Treyer, Andrea and De Pascale, Martina and Hebeisen, Paul and Hamburger, Matthias and Wymann, Matthias P.. (2021) Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. RSC Medicinal Chemistry, 12 (4). pp. 579-583.

2020

Borsari, Chiara and Keles, Erhan and Rageot, Denise and Treyer, Andrea and Bohnacker, Thomas and Bissegger, Lukas and De Pascale, Martina and Melone, Anna and Sriramaratnam, Rohitha and Beaufils, Florent and Hamburger, Matthias and Hebeisen, Paul and Löscher, Wolfgang and Fabbro, Doriano and Hillmann, Petra and Wymann, Matthias P.. (2020) 4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of neurological disorders. Journal of Medicinal Chemistry, 63 (22). pp. 13595-13617.

2017

Beaufils, Florent and Cmiljanovic, Natasa and Cmiljanovic, Vladimir and Bohnacker, Thomas and Melone, Anna and Marone, Romina and Jackson, Eileen and Zhang, Xuxiao and Sele, Alexander and Borsari, Chiara and Mestan, Jurgen and Hebeisen, Paul and Hillmann, Petra and Giese, Bernd and Zvelebil, Marketa and Fabbro, Doriano and Williams, Roger L. and Rageot, Denise and Wymann, Matthias P.. (2017) 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry, 60 (17). pp. 7524-7538.

2016

Beaufils, Florent and Rageot, Denise and Melone, Anna and Sele, Alexander and Lang, Marc and Mestan, Juergen and Ettlin, Robert A. and Hillmann, Petra and Cmiljanovic, Vladimir and Walter, Carolin and Singer, Elisabeth and Nguyen, Hoa H. P. and Hebeisen, Paul and Fabbro, Dorian and Wymann, Matthias P.. (2016) Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620. Cancer Research, 76 (14). 393A.

Beaufils, Florent and Rageot, Denise and Melone, Anna and Lang, Marc and Mestan, Jürgen and Cmiljanovic, Vladimir and Hillmann, Petra and Hebeisen, Paul and Fabbro, Doriano and Wymann, Matthias P.. (2016) Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor. Cancer Research, 76 (14). p. 1336.

2015

Cmiljanovic, Vladimir and Ettlin, Robert A. and Beautils, Florent and Dieterle, Walter and Hillmann, Petra and Mestan, Juergen and Melone, Anna and Bohnacker, Thomas and Lang, Marc and Cmiljanovic, Natasa and Giese, Bernd and Hebeisen, Paul and Wymann, Matthias P. and Fabbro, Doriano. (2015) PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. Cancer Research, 75 (15). p. 4514.

Cmiljanovic, Vladimir and Cmiljanovic, Natasa and Marone, Romina and Beaufils, Florent and Zhang, Xuxiao and Zvelebil, Marketa and Hebeisen, Paul and Lang, Marc and Mestan, Juergen and Melone, Anna and Bohnacker, Thomas and Gaudio, Eugenio and Tarantelli, Chiara and Bertoni, Francesco and Ritschard, Reto and Pretre, Vincent and Wicki, Andreas and Fabbro, Doriano and Hillmann, Petra and Williams, Roger and Giese, Bernd and Wymann, Matthias P.. (2015) PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. Cancer Research, 75 (15). p. 2664.